Stock DNA
Pharmaceuticals & Biotechnology
AED 24,333 Million (Small Cap)
13.00
NA
0.00%
-0.22
11.03%
1.33
Revenue and Profits:
Net Sales:
7,262 Million
(Quarterly Results - Mar 2026)
Net Profit:
415 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-26.67%
0%
-26.67%
6 Months
-39.24%
0%
-39.24%
1 Year
-47.75%
0%
-47.75%
2 Years
0%
0%
0.0%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
PureHealth Holding Pjsc for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
32.50%
EBIT Growth (5y)
-20.17%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.36
Sales to Capital Employed (avg)
1.05
Tax Ratio
3.66%
Dividend Payout Ratio
30.00%
Pledged Shares
0
Institutional Holding
0.01%
ROCE (avg)
9.89%
ROE (avg)
7.13%
Valuation key factors
Factor
Value
P/E Ratio
13
Industry P/E
Price to Book Value
1.41
EV to EBIT
10.90
EV to EBITDA
5.73
EV to Capital Employed
1.52
EV to Sales
0.80
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
13.95%
ROE (Latest)
11.03%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Dow Theory
No Trend
No Trend
OBV
Bullish
Bullish
Shareholding Snapshot : Mar 2026
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.01%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
7,262.30
6,581.00
10.35%
Operating Profit (PBDIT) excl Other Income
917.20
986.20
-7.00%
Interest
234.60
214.00
9.63%
Exceptional Items
0.00
0.00
Consolidate Net Profit
414.90
505.20
-17.87%
Operating Profit Margin (Excl OI)
57.60%
89.90%
-3.23%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is 10.35% vs 7.62% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is -17.87% vs 2.98% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
27,312.00
25,848.20
5.66%
Operating Profit (PBDIT) excl Other Income
3,809.10
3,470.60
9.75%
Interest
864.80
847.60
2.03%
Exceptional Items
482.10
99.30
385.50%
Consolidate Net Profit
2,020.10
1,715.70
17.74%
Operating Profit Margin (Excl OI)
73.30%
73.90%
-0.06%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 5.66% vs 57.62% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 17.74% vs 77.79% in Dec 2024
About PureHealth Holding Pjsc 
PureHealth Holding Pjsc
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






